Transforming growth factor-b 1 (TGF-b1) signaling in tumor cells has been implicated in tumor angiogenesis and metastasis by regulating matrix proteolysis. Although MMP-9/gelatinase-B is an important component of these TGF-b1 responses, the mechanism of its regulation is not well understood. Here, we present evidence that TGF-bactivated protein kinase 1 (TAK1) is critical for TGF-b regulation of MMP-9 and the metastatic potential of breast cancer cell line MDA-MB-231. We found that suppression of TAK1 signaling by dominant-negative (dn) TAK1 or RNA interference (siRNA) reduces expression of MMP-9 and tumor cell invasion, without growth inhibition in cell culture. The orthotopic xenograft studies in SCID mice showed that suppression of TAK1 signaling by dn-TAK1 reduces tumor growth and formation of lung metastases. QJ;Dn-TAK1 reduced the proliferation Ki-67 index and neovasculature of orthotopic xenografts. TAK1-mediated regulation of MMP-9 involves NF-jB signaling. Dn-TAK1 reduces NF-jB transcriptional response and inhibition of NF-jB reduces expression of MMP-9 and activity of the MMP-9 promoter reporter. Together, these findings suggest that TAK1 contributes to TGF-b1-mediated tumor angiogenesis and metastasis via a mechanism involving the TAK1-NF-jB-MMP-9 pathway.
Introduction
Cancer progression and metastasis have been linked to changes in tumor microenvironment and inflammation. Transforming growth factor-b1 (TGF-b1) cytokine regulates the composition of extracellular matrix (ECM), matrix proteolysis and inflammatory responses (Ashcroft et al., 1999; Dunker and Krieglstein, 2000) . TGF-b1 is a potent inhibitor of epithelial cell growth and functions as tumor suppressor at early stages of cancer, whereas, at the late stages of cancer, TGF-b1 promotes tumor spreading by enhancing invasion and angiogenesis (Roberts and Wakefield, 2003) . Given this dual function of TGF-b1 in cancer progression, it is important to determine specific components of the TGF-b pathway contributing to tumor invasion and metastasis.
TGF-b1 signals through serine/threonine kinase transmembrane type I and type II receptors (Massague, 1998) . TGF-b1 binding to the receptor complex triggers activation of type I receptor, termed activin-like receptor kinase 5 (ALK5), which initiates downstream signaling involving Smad transcription factors, mitogen-activated protein kinases (MAPKs) and PI3K-Akt signaling (Derynck and Zhang, 2003) . ALK5 phosphorylates receptor-associated Smad2 and Smad3 (R-Smads) and induces translocation of R-Smads and Smad4 to the nucleus (Massague, 1998) . TGF-b-mediated activation of MAPKs may involve TGF-b-activated kinase 1 (TAK1) or small GTPases (Derynck and Zhang, 2003) . Activation of PI3K-Akt signaling by TGF-b1 (Bakin et al., 2000; Dumont et al., 2003) requires small r-like GTPases (Bakin et al., 2000) . MAPK and PI3K-Akt signaling cascades are activated independently of Smads (Bhowmick et al., 2001; Dumont et al., 2003) . All three cascades have been implicated in regulation of tumor microenvironment and invasion, and can potentially contribute to the metastatic function of TGF-b1 (Roberts and Wakefield, 2003) .
TAK1, a mitogen-activated protein kinase kinase kinase (MAP3K), was identified as a kinase that mediates TGF-b signaling to MAPKs p38 and c-Jun N-terminal kinase (JNK) (Yamaguchi et al., 1995) . TAK1 is also involved in bone morphogenetic protein (BMP) signaling (Shibuya et al., 1998) as well as in inflammatory and innate immune responses (Sato et al., 2005) . TAK1 is activated by association with TAK1-binding proteins (TAB1-3) (Singhirunnusorn et al., 2005) . In addition to activation of MAPKs (extracellular signal-regulated kinase (ERK), JNK and p38), TAK1 is also important for activation of nuclear factorkB (NF-kB) transcription factor (Karin and Greten, 2005) .
TGF-b1 enhances tumor invasion by stimulating matrix metalloproteinases (MMPs) and the urokinase plasminogen activator (uPA) system (Farina et al., 1998; Janji et al., 1999; Huang et al., 2000 Huang et al., , 2004 Johansson et al., 2000; Suarez-Cuervo et al., 2004) . Invasion and metastasis of cancer cells have been associated with TGF-b1-mediated upregulation of MMP-9/gelatinase-B (Farina et al., 1998; Suarez-Cuervo et al., 2004; Safina et al., 2007) . MMP-9 contributes to tumor angiogenesis by promoting recruitment of endothelial cells (Bergers et al., 2000) and pericytes (Chantrain et al., 2004) . Indeed, TGF-b1-mediated tumor angiogenesis is significantly reduced when MMP-9 is suppressed by RNA interference (short interfering RNA, siRNA) (Safina et al., 2007) . The molecular mechanism of MMP-9 regulation by TGF-b1 is still not well understood. Early studies with kinase inhibitors have implicated p38MAPK in MMP-9 regulation by TGF-b1 in breast cancer cells (Farina et al., 1998; Suarez-Cuervo et al., 2004) . Recent studies with dominant-negative (dn) mutants of MAPKs have shown that p38MAPK is dispensable, whereas MEK-ERK contributes to TGF-b1 regulation of MMP-9 (Safina et al., 2007) . Ras-ERK signaling has been also implicated in regulation of MMP-9 in fibroblasts and epithelial cell lines (Gum et al., 1996; Himelstein et al., 1997; Iyer et al., 2005) . In human mammary epithelial cells, however, expression of constitutively active (ca) H-RasV12 is not sufficient to induce MMP-9 (Dechow et al., 2004) , suggesting involvement of additional factors in MMP-9 regulation.
The present study investigated the role of TAK1 in expression of MMP-9 and metastasis using the orthotopic xenograft model of breast cancer cells in severe combined immunodeficiency (SCID) mice. We provide evidence that TAK1 is critical for TGF-b regulation of MMP-9 and the metastatic potential of breast cancer cell line MDA-MB-231. Disruption of TAK1 signaling in tumor cells by dn-TAK1 reduced tumor angiogenesis and metastases to lungs. The analysis of TAK1 downstream effectors implicated NF-kB in MMP-9 regulation. These findings indicate that TAK1-NF-kB signaling is important for TGF-b1-mediated regulation of MMP-9, tumor angiogenesis and metastasis.
Results
TAK1 is required for regulation of MMP-9 by TGF-b1 TGF-b signaling in breast cancer MDA-MB-231 cells has been implicated in tumor invasion (Farina et al., 1998) , bone metastasis (Yin et al., 1999) and tumor angiogenesis (Safina et al., 2007) . In these cells, TGF-b1 upregulates MMP-9/gelatinase-B and suppression of MMP-9 by siRNA inhibits TGF-b-mediated matrix proteolysis, invasion and angiogenesis (Safina et al., 2007) . This study has raised a question regarding the molecular mechanism of MMP-9 regulation by TGF-b1 as inhibition of p38MAPK, JNK or Smad4 did not affect MMP-9 levels (Safina et al., 2006) . Here, we examined whether TAK1 contributes to MMP-9 regulation by TGF-b1. MDA-MB-231 cells were transduced with retroviruses encoding enhanced green fluorescent protein (EGFP) or kinase-inactive TAK1-K63W and EGFP. The immunoblot analysis showed that dn-TAK1 was expressed at the levels comparable with endogenous TAK1 (Figure 1a ) and did not affect phosphorylation of Smad2/3 and ERK1/2 (Figure 1d ). Gelatin zymography revealed a significant reduction of secreted proMMP-9 in 48 h-conditioned media from the dn-TAK1-expressing cells compared to EGFP control (Figure 1b) . Expression of MMP-9 was not reduced in cells expressing dn-p38MAPK (Figure 1b) , although phosphorylation of HSP27 was blocked (Safina et al., 2007) . Dn-TAK1 reduced proMMP-9 levels even in cells untreated with TGF-b1 (Figure 1b) . It has been reported that autocrine TGF-b1 signaling in MDA-MB-231 cells contributes to cell migration (Dumont et al., 2003) and expression of MMP-9 (Safina et al., 2007) . Thus, TAK1 may mediate regulation of MMP-9 by autocrine TGF-b1 signaling, although the role of other pathways could not be excluded.
The uPA/uPAR system is stimulated by TGF-b1 in MDA-MB-231 cells (Farina et al., 1998; Safina et al., 2007) and can regulate activation or expression of MMP-9 (Van den Steen et al., 2002) . The reverse transcription (RT)-PCR analysis showed that dn-TAK1 did not affect the induction of uPA and uPAR mRNA levels by TGF-b1 (Supplementary Figure 1A) . TAK1 is activated by binding partners TAB1-3 and expression of dn-TAK1 could potentially interfere with TAK1-independent function of these proteins. To control this possibility, TAK1 was suppressed using RNA interference. siRNA to TAK1 (si-TAK1) reduced TAK1 protein level by fourfold but did not affect p38MAPK, conversely, si-p38 reduced protein level of p38 by fivefold but did not suppress TAK1 (Figure 1c) . Zymography studies revealed a reduction of secreted proMMP-9 in si-TAK1-transfected MDA-MB-231 compared to scrambled siRNA and si-p38MAPK ( Figure 1d ). Our previous studies have shown that ca-TGF-b type I receptor ALK5-T204D increases proMMP-9 levels by 10-fold in MDA-MB-231 cells (Safina et al., 2007) . To address the role of TAK1 in this effect, we measured mRNA and protein levels of TAK1 in EGFP control and the ca-ALK5 cells. The analysis showed no regulation of TAK1 levels by ca-ALK5 (data not shown). We then asked whether TAK1 function is involved. Transfection of si-TAK1 or sip38 suppressed corresponding proteins by approximately fourfold compared to scramble control (Supplementary Figure 1B ). Zymography showed that si-TAK1 significantly reduced proMMP-9, whereas si-p38 had no effect (Figure 1e ). These findings confirm the studies with dn-TAK1 and indicate that TAK1 is required for regulation of MMP-9 by TGF-b1 signaling.
TAK1 contributes to invasion and metastatic potential of breast cancer cells Autocrine TGF-b1 signaling regulates focal matrix proteolysis and invasion of MDA-MB-231 cells, and suppression of MMP-9 reduces these effects (Safina et al., 2007) . To determine whether dn-TAK1 contributes to focal matrix proteolysis, control EGFP and dn-TAK1 MDA-MB-231 cells were incubated on fluorescently labeled gelatin, then fixed and stained for (Safina et al., 2007) , whereas the dn-TAK1 cells lacked these footprints (Figure 2a ). 
TAK1 in TGF-b-mediated metastasis
A Safina et al Thus, dn-TAK1 inhibits proteolytic activity of MDA-MB-231 cells at cell-matrix adhesions. Invasive properties of dn-TAK1-expressing cells were evaluated using Matrigel invasion assays. The dn-TAK1 cells showed nearly twofold reduction in invasion of Matrigelcoated transwells compared to the EGFP control cells (Figure 2b ). Thus, TAK1 is required for focal matrix proteolysis and invasion of breast cancer cells. Because autocrine TGF-b1 signaling affects metastatic potential of tumor cells, we examined the role of TAK1 in giving raise to lung metastasis using the tail-vein injection model in SCID mice. Control and dn-TAK1 cells were injected into the tail vein of SCID mice and 4 weeks later the lungs were stained with Indian ink. The analysis showed a significant reduction in tumor cell colonies on lung surfaces of SCID mice injected with dn-TAK1 cells compared to control EGFP (Figure 2c ). These findings show that TAK1 is involved in the process of trapping and taking residence at lungs of breast cancer MDA-MB-231 cells.
TAK1 contributes to tumor growth
To investigate the specific role of TAK1 in the metastatic process, control and dn-TAK1 cells were placed at the orthotopic site in the mammary gland fat pads of SCID mice. The appearance of palpable tumors was significantly delayed in the dn-TAK1 xenografts compared to EGFP controls, indicating the role of TAK1 in tumor take (Figure 3a) . The rate of tumor growth of dn-TAK1 xenografts was also significantly reduced ( Figure 3b ). Immunohistochemical analysis of Ki-67 staining showed that dn-TAK1 reduced the Ki-67 proliferation index by 22.5%, 0.55 versus 0.71 in EGFP control, Po0.01 (Figure 3c ). In cell culture, however, dn-TAK1 did not affect cell proliferation measured using MTS assay (Figure 3d ). Collectively, these findings indicate that TAK1 contributes to initial steps and sustained tumor growth at the orthotopic site, and this is associated with a reduction of in vivo tumor cell proliferative activity.
TAK1 is involved in tumor angiogenesis
Tumor growth in vivo depends on the tumor vasculature (Folkman, 1971) and MMP-9 functions as an important component of tumor angiogenesis by mobilizing vascular endothelial growth factor deposited in ECM (Bergers et al., 2000) . Suppression of MMP-9 by siRNA in MDA-MB-231 cells reduces TGF-b-mediated tumor growth and angiogenesis (Safina et al., 2007) . To determine whether dn-TAK1 affects tumor vasculature, the tissue sections of EGFP control and dn-TAK1 orthotopic xenografts were stained with CD31/PECAM antibody. The immunohistochemistry analysis showed (Figure 4a ). The CD31 staining was quantified for the highest number of discrete CD31-positive microvessels or 'microvessel hot spots' (Weidner et al., 1991) . The analysis revealed a nearly 50% reduction of the microvessel density in the dn-TAK1 xenografts compared to EGFP control, 38 microvessels per 0.2 mm 3 field in dn-TAK1 versus 68 in EGFP, Po0.05 (Figure 4b ). Interestingly, a comparable reduction of the microvessel density was observed in cells expressing dn-ALK5 or si-MMP-9 (Safina et al., 2007) . The orthotopic xenografts of MDA-MB-231 cells metastasize to lungs (Safina et al., 2007) . Quantification of lung-surface tumor colonies showed that dn-TAK1 cells formed significantly fewer lung colonies compared to control EGFP cells (Figure 4c ). Together, these findings indicate that TAK1 contributes to the development of tumor vasculature and to the ability of breast cancer cells to establish colony at the distal site (lungs).
TAK1 mediates NF-kB signaling in regulation of MMP-9 by TGF-b1 MMP-9 is regulated at the transcriptional and posttranscriptional levels (Van den Steen et al., 2002) . In MDA-MB-231 cells autocrine TGF-b1 signaling regulates mRNA levels of MMP-9 (Safina et al., 2007) . MMP-9 transcription is regulated by NF-kB and AP-1 transcription factors via specific sites within a 600 bp region immediately upstream of the transcription start site of the MMP-9 promoter (Sato and Seiki, 1993; Himelstein et al., 1997) . Because TAK1 is known to affect NF-kB and AP-1 (Karin and Greten, 2005) , we examined whether TAK1 is involved in MMP-9 transcription. MDA-MB-231 cells were transfected with a luciferase reporter containing a 670 bp fragment of the human MMP-9 promoter (Himelstein et al., 1997) . Cells expressing dn-TAK1 showed a significant reduction in the MMP-9 reporter activity compared to EGFP control and cells expressing dn-p38MAPK (Figure 5a ). In consideration of the downstream effector of TAK1, our studies ruled out the involvement of p38MAPK and JNK (Figure 1 ; Safina et al., 2007) . In addition, dn-TAK1 did not reduce the levels of active ERK1/2 (Figure 1a) , although ERK signaling contributes to MMP-9 expression in MDA-MB-231 cells (Safina et al., 2007) . These results suggested that TAK1 regulate MMP-9 via a different pathway. Given that MDA-MB-231 cells show high levels of the NF-kB transcriptional activity (Nakshatri et al., 1997) and NF-kB is required for MMP-9 expression (Sato and Seiki, 1993) , we examined whether dn-TAK1 affects NF-kB transcriptional activity. The dn-TAK1 cells showed significant reduction of the NF-kB-transcription reporter activity whereas dn-p38MAPK had no effect (Figure 5b ), indicating that TAK1 regulates NF-kB transcriptional activity. To examine whether NF-kB mediates TAK1 regulation of MMP-9, MDA-MB-231 cells were transfected with the MMP-9 luciferase reporter and treated with a cell permeable quinazoline compound that acts as a specific inhibitor of NF-kB transcriptional activation (Tobe et al., 2003) . NF-kB inhibitor reduced the MMP-9 luciferase-reporter activity in a dose-dependent manner (Figure 5c ). To test whether inhibition of NF-kB affects TGF-b-mediated secretion of MMP-9, we used ALK5-T204D-expressing MDA-MB-231 cells that secrete high level of MMP-9 (Safina et al., 2007) . Treatment of the ALK5-T204D cells with increasing amounts of the NF-kB inhibitor reduced secretion of MMP-9 (Figure 5d ). This is consistent with the effect of the ). (c) Lung surface metastases from orthotopic xenografts placed in the fat pads of SCID female mice, n ¼ 6 mice per group. P-values were calculated using analysis of variance test.
TAK1 in TGF-b-mediated metastasis
A Safina et al NF-kB inhibitor on the MMP-9 promoter activity ( Figure 5c ). Together, these findings indicate an important role of TAK1-NF-kB signaling in MMP-9 expression in breast cancer cells.
Discussion
The present study provides evidence for a critical role of TGF-b-activated protein kinase 1 (TAK1) in TGF-bmediated regulation of MMP-9 and the metastatic potential of breast cancer cells. Suppression of TAK1 by siRNA or forced expression of kinase-inactive TAK1-K63W (dn-TAK1) reduced expression of MMP-9 and tumor invasion without an effect on the uPA/uPAR system or cell growth. Dn-TAK1 significantly compromised the growth of orthotopic tumor xenografts in SCID mice, reduced tumor angiogenesis and formation of lung metastases. Cells expressing dn-TAK1 showed a reduction in NF-kB transcriptional activity and inhibitors of NF-kB blocked TGF-bmediated secretion of MMP-9. Thus, TAK1-NF-kB signaling is critical for TGF-b-mediated tumor invasion, angiogenesis and metastasis. Solid evidence implicates MMP-9/gelatinase-B and TGF-b1 in cancer progression and metastasis by contributing to both tumor angiogenesis and tumor invasion. Although TGF-b1 has been shown to regulate MMP-9, the exact molecular mechanism is not well understood. Important novel finding of our studies is that MMP-9 regulation by TGF-b1 requires TAK1. Previous studies have shown that TAK1 is involved in TGF-b signaling to MAPKs p38 and JNK (Yamaguchi et al., 1995) . Our studies indicate that p38 and JNK are dispensable for MMP-9 expression in breast cancer MDA-MB-231 cells (Figure 1 ; Safina et al., 2007) . Although ERK contributes to TGF-b1-mediated regulation of MMP-9 (Safina et al., 2007) , dn-TAK1 reduced MMP-9 without an effect on ERK (Figure 1 ). The analysis of the TGF-b1-TAK1-MMP-9 pathway in breast cancer cell lines revealed that the ability of TGF-b1 to upregulate MMP-9 in tumor cells correlates with high levels of TAK1 protein (Supplementary Figure  2) . Together these findings indicate an essential role of TAK1 in TGF-b1-mediated regulation of MMP-9.
Our findings suggest a critical role of NF-kB in TAK1-dependent expression of MMP-9 ( Figure 5 ). Dn-TAK1 reduced the activity of the NF-kB transcriptional reporter and an inhibitor of NF-kB blocked TGF-b1-mediated regulation of MMP-9. The conundrum of these intriguing findings is that TGF-b1 and NF-kB are TAK1 in TGF-b-mediated metastasis A Safina et al components of opposite biological responses. TGF-b1 is a well-known anti-inflammatory cytokine (Ashcroft et al., 1999; Dunker and Krieglstein, 2000) , whereas NF-kB is a critical component of pro-inflammatory responses (Karin and Greten, 2005) . In normal epithelial cells, TGF-b1 negatively regulates NF-kB transcriptional activity (Arsura et al., 1997; Azuma et al., 1999) , while pro-inflammatory cytokines repress Smad-dependent transcription (Nagarajan et al., 2000; Verrecchia et al., 2003) . The anti-inflammatory effect of TGF-b1 is likely mediated by Smads, as targeted disruption of Smad3 alleviates inflammation (Ashcroft et al., 1999) and Smad3/Smad4 mediates suppression of NF-kB signaling in renal inflammation (Bitzer et al., 2000; Wang et al., 2005) . In tumor cells, however, TGF-b1 can activate NF-kB transcriptional response (Arsura et al., 2003; Deckers et al., 2006) . In agreement with our studies, TAK1 mediates NF-kB regulation by TGF-b1 in hepatocellular carcinoma cells (Arsura et al., 2003) . Interestingly, MDA-MB-231 breast cancer cells express high levels of NF-kB transcriptional activity (Sliva et al., 2002) and ca-Ras-ERK signaling (Ogata et al., 2001) . Ras-ERK signaling is known to inhibit Smad transcriptional responses (Kretzschmar et al., 1999; Saha et al., 2001) . In fact, a Smad-dependent growth-inhibitory response to TGF-b1 is significantly reduced in MDA-MB-231 cells (de Winter et al., 1997) . A provocative idea is that inactivation/reduction of Smad signaling might contribute to a positive interaction between TGF-b1, TAK1 and NF-kB in regulation of MMP-9 in tumor cells.
Tumor xenograft studies suggest an important role of TAK1 in tumor take and tumor growth (Figure 3) . CD31 staining showed a significant reduction in the microvessel density in the dn-TAK1 xenografts compared to controls (Figure 4a and b) . These findings suggest that the effects of dn-TAK1 on tumor take/ growth are likely associated with a reduction of tumor vascularization. Phenotypically similar effects were produced by dn-ALK5/TbRI or si-MMP-9 (Safina et al., 2007) . These findings suggest a novel function for TAK1 in tumor angiogenesis downstream of TGFb1 and, possibly, within inflammatory pathways in tumor cells. Although MMP-9 is evidently important angiogenic factor (Bergers et al., 2000; Van den Steen et al., 2002) , TAK1-NF-kB signaling may also regulate expression of other pro-angiogenic factors such as uPA, COX2 and IL8 (Sliva et al., 2002; Karin and Greten, 2005) .
In conclusion, our studies suggest that in tumor cells TGF-b1-TAK1 signaling cooperates with Ras and pro-inflammatory pathways in tumor invasion, angiogenesis and metastasis. TGF-b1-TAK1 and Ras-ERK may stimulate AP-1 transcription factor, while TGF-b1 and inflammatory signaling regulate NF-kB. MMP-9 is a critical target of these pathways, although other molecular targets may also be important. The link between TGF-b1, NF-kB and MMP-9 suggests that NF-kB inhibitors are potential inhibitors of TGF-b1-mediated angiogenesis. TAK1 may also contribute to development of bone metastasis in patients with breast and prostate cancers as both TGF-b1 and NF-kB are involved in bone metastasis. Thus, TAK1 may represent a potential biomarker of invasive and metastasis-capable cancers and a target for anticancer therapy.
Materials and methods
Antibodies, plasmids and other reagents TGF-b1 was obtained from R&D Systems (Minneapolis, MN, USA). The antibodies were as follows: rat anti-mouse CD31 and Smad2/3 from BD Biosciences (PharMingen, CA, USA); phospho-Smad2, phospho-p38 MAPK, phospho-ERK1/2 from Cell Signaling Technology (MA, USA); Ki-67 from Abcam, catalog no. ab833; glyceraldehyde-3-phosphate dehydrogenase (GAPDH, sc25778) from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Matrigel-coated chambers were from BD Biosciences, catalog no. 354480. Kinase inhibitors were obtained from Calbiochem (San Diego, CA, USA): U0126 for MEK; NF-kB activation inhibitor catalog no. 481406. siRNA targeting human TAK1 and p38MAPK were purchased from Dharmacon, Inc. (Lafayette, CO, USA). A scramble control RNA duplex labeled with rhodamine was obtained from Qiagen (Chatsworth, CA, USA). Kinaseinactive TAK1-K63W was a gift from Dr Hiroaki Sakurai (Sakurai et al., 1999) . cDNA encoding TAK1-K63W was subcloned at EcoRI/SmaI sites into retroviral vector pBMN-EGFP. Retroviral vector pBMN-EGFP and constructs encoding Flag-tagged p38a-AF and HA-tagged ALK5-T204D are described (Bakin et al., 2002) .
Cell culture
Human breast cancer MDA-MB-231 cells were obtained from American Tissue Culture Collection (ATCC) and cultured as recommended by ATCC. MDA-MB-231-p38AGF and MDA-MB-231-ALK5-T204D cells are described (Safina et al., 2007) .
Retroviral infection
MDA-MB-231 cells were infected in presence of 6 mg ml À1 of polybrene with amphotropic retroviruses produced in Phoenix cells as previously described (Bakin et al., 2002) . GFP-positive cells were selected by fluorescence-activated cell sorting.
Short interference RNA Cells were transfected with RNA duplexes using Oligofectamine reagents (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. The media was replenished next day. The cells were grown for additional 48 h in the absence or presence of 2 ng ml À1 TGF-b1 followed by gelatin zymography and immunoblotting.
Immunoblot analysis Cells were incubated in medium containing 5% serum for 24 h prior to treatment with 2 ng ml À1 TGF-b1. Kinase inhibitors were added 1 h prior to treatment with TGF-b1. Cells were lysed in buffer: 20 mM Tris (pH 7.4), 137 mM NaCl, 1% NP-40, 10% glycerol, 20 mM NaF, 1 mM Na orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 2 mg ml À1 aprotinin and 2 mg ml À1 leupeptin. Immunoblot analyses of protein extracts were performed as described (Bakin et al., 2002) .
Transcription assay
The luciferase reporters were as follows: MMP-9-Lux containing a 670 bp fragment of the human MMP-9 promoter in pGL2 vector was a gift from J Bromberg (Memorial SloanKettering Cancer Institute, New York, NY, USA); the NF-kB luciferase reporter (catalog no. 631904) was obtained from Clontech Laboratories Inc. (Mountain View, CA, USA). The transcriptional assays were performed as described (Bakin et al., 2004) . Firefly luciferase (Luc) and Renilla reniformis luciferase activities in cell lysates were determined using the Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA) according to the manufacturer's protocol in a Monolight 2010 luminometer (Analytical Luminescence Laboratory, San Diego, CA, USA). Luc activity was normalized to Renilla activity and presented as relative luciferase units. All assays were done in triplicate wells and each experiment was repeated at least two times.
RT-PCR analysis RT-PCR was performed as described (Safina et al., 2007) . RNA extraction was performed using Versagene RNA kit (Centra, Minneapolis, MN, USA). Amplification of transcripts was performed using 50 ng ml À1 of total RNA and one-step RT-PCR system from Invitrogen according to the manufacturing protocol. Primer sequences: b-actin (ACTB), Acc no. ;NM_007393, forward: GCTGGTCGTCGACAACGGCTC, reverse: CAAACATGATCTGGGTCATCTTTTC; uPA, Acc no. NM_002658, forward: TGTGAGATCACTGGCTTT GG, reverse: AGGCCATTCTCTTCCTTGGT; uPAR, Acc no. NM_002659, forward: TGTTGCAGCATTTCAGG AAG, reverse: AGCTATCGGACTGGCTTGAA.
Proliferation assay
Proliferation of cells was evaluated using MTS assays according to manufacturer's protocol (Promega).
Matrigel invasion assay
The assay was performed as described (Safina et al., 2007) . Cells were mildly trypsinized and washed twice in Iscove's minimal essential media (IMEM) with 0.1% bovine serum albumin (BSA). Cells (1 Â 10 5 ) were seeded in the upper chamber coated with Matrigel (Calbiochem). The lower chamber was filled with 0.6 ml IMEM containing 0.1% BSA. TGF-b1 (1 ng ml
À1
) was added to the lower chamber. After 20 h of incubation, the nonmigrating cells in the upper chamber were scraped away and cells present on the lower surface of the insert were stained with Diff-Quik Stain (Biochemical Sciences Inc., Swedesboro, NJ, USA). Invading cells were counted from five random fields in three wells. Experiments were repeated at least two times.
Gelatin zymography
The assay was performed as described (Safina et al., 2007) . Conditioned media of cells incubated in serum-free IMEM for 48 h was removed and centrifuged. Sodium dodecyl sulfatepolyacrylamide gel electrophoresis gels were copolymerized with gelatin at a final concentration of 1 mg ml
À1
. After electrophoresis, the gels were renaturated in 2.5% Triton X-100 and incubated at 37 1C for 24 h in 5 mM CaCl 2 and 50 mM Tris-HCl buffer (pH 7.5), containing 0.05% NaN 3 . The gels were stained with 0.5% Coomassie blue R-250 and destained in 10% methanol and 5% acetic acid in water. Gelatinolytic activities were detected as transparent bands on the blue background. The band densities were evaluated using NIH Image software.
ECM degradation
Oregon Green 488-labeled gelatin was purchased from Molecular Probes (Carlsbad, CA, USA). Gelatin-coated coverslips were prepared essentially as described (Safina et al., 2007) . Briefly, glass coverslips were coated with 0.2 mg ml À1 Oregon Green 488-labeled gelatin. Gelatin was immediately crosslinked with ice-cold 0.5% glutaraldehyde (Sigma, St Louis, MO, USA) in phosphate-buffered saline (PBS) for 15 min at 4 1C. Coverslips were gently washed with PBS and incubated with 5 mg ml À1 sodium borohydride (Sigma) in PBS for 3 min. The coverslips were sterilized in 70% ethanol for 15 min, washed in PBS and then incubated in serum-free medium for 1 h at 37 1C. Cells were grown on the coverslips for various time periods and processed to fluorescence microscopy procedures.
Animal studies using a tail-vein injection model
The studies were performed as described (Safina et al., 2007) . Female SCID/CB17 mice, 8 weeks of age, were obtained from a colony of SCID/CB17 mice that was bred and maintained at the Department of Laboratory Animal Resources facility at the Roswell Park Cancer Institute (RPCI). All animals were kept 3-5 mice per cage in microisolator units and provided with water and food ad libitum according to a protocol approved by the Institute Animal Care and Use Committee at RPCI. The facility has been certified by the American Association for Accreditation of Laboratory Animal Care and in accordance with current regulation and standards of the US Department of Agriculture and the US Department of Health and Human Services.
Exponentially growing breast cancer cells (2.5 Â 10 6 ) in 0.2 ml of sterile Hank's solution were injected using 28 gauge needle into a tail vein of 8-week-old female SCID/CB17 mice. Mice were killed 4 weeks thereafter. Lungs were stained with Indian black ink and tumor colonies on lung surfaces were counted as described (Wexler, 1966) .
Animal studies using an orthotopic xenograft model The studies were performed as described (Safina et al., 2007) . Exponentially growing tumor cells (1 Â 10 6 ) in 0.1 ml Hank's buffered salt solution were inoculated into the surgically exposed mammary fat pad (m.f.p.) of 7-to 8-week-old female SCID mice. The growth of primary tumors was monitored by measuring tumor diameters with electronic calipers every 3-4 days continuously from the third week after injection. Volumes were calculated using the formula (length) Â (width) 2 /2. Primary tumors were removed at 1 cm diameter, typically 30-35 days after appearance of palpable tumors. After 4-5 weeks, the mice were killed, lungs, bones, spleens, livers were collected and histological analysis was performed at the RPCI pathology facility.
Immunohistochemistry
The immunohistochemical studies were performed as described (Safina et al., 2007) . Tumor specimens were fixed immediately in 10% (v/v) formalin and then embedded in paraffin. For Ki-67 staining, formalin-fixed tissue sections were incubated for 1 h at room temperature with the rabbit polyclonal primary antibodies to human Ki-67. Biotinylated secondary goat anti-rabbit antibodies were applied for 30 min followed by 30 min incubation with the ABC reagent (Vector Labs, Burlingame, CA, USA). Ki-67 labeling index was calculated as the percentage of positive tumor nuclei divided by the total number of tumor cells examined. At least 1000 tumor cells per specimen were examined in five random fields using light microscopy at 400-fold magnification. For CD31 staining harvested tumors were fixed in Zink fixative (BD Biosciences) overnight and then processed for paraffin sections. The rat anti-mouse primary antibody to CD31 (BD TAK1 in TGF-b-mediated metastasis A Safina et al Biosciences) was applied for 1 h at room temperature followed by 30 min incubations with biotinylated secondary anti-rat antibody (BD Biosciences) and the streptavidin complex (Zymed Lab Inc., San Francisco, CA, USA). The microvessel density was analysed as described (Weidner et al., 1991) . Briefly, tumor sections were scanned at Â 100 magnification for the areas containing the highest number of discrete CD31-positive microvessels ('microvessel hot spots'). Necrotic and immediately adjacent areas where microvessels are sparse were excluded from counting. CD31-positive (brown stain) vessels were counted at Â 400 magnification in eight fields of each tumor section. The results were presented as mean number of microvessels/field (0.2 mm 3 )7s.d.
Statistical analysis
Continuous data were compared using the Student's t-test. Differences were considered significant when Po 0.05.
Abbreviations
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